MYC and Miyoshi myopathy: Even though we used adoptive tumor cells transfer models in which the immune system does not co-evolve with the tumor progression and induced immune tolerance towards the tumor might therefore be reduced, both models engraft in fully immunocompetent mice reflecting a highly aggressive and progressed (in the case of VK*MYC also Bortezomib resistant) MM disease.